Download now: Cannabis Cash

How to Profit From the End of Aging

Why This Anti-Aging Stock Could Double in Three Weeks

Written by Jeff Siegel
Posted August 6, 2020

Kane Tanaka is 117 years old.

She’s believed to be the oldest-known living person in the world.

But it’s only a matter of time before 117 is no longer considered old — but middle aged.

At least that’s what MIT-trained scientist David Sinclair believes.

Known as one of the leading experts in the field of aging, Sinclair is the guy who discovered the survival-circuit theory. And he says that getting cold, employing extreme workouts, and occasional fasting engage this “survival circuit” in our bodies, which results in certain cells increasing their defenses that keep you alive.

It’s a fascinating theory that has been written about and studied quite extensively, although it still has yet to be proven in an FDA clinical trial setting.

The only significant trials being conducted right now in the field of aging are the trials being conducted by a company that’s developed a new cell-based treatment designed to both extend life spans and end age-related chronic diseases such as arthritis, diabetes, and glaucoma. 

Interestingly, that company is publicly traded, which is why it has my attention. 

It should have your attention, too.

Think about it …

Right now, there’s a company that’s developed a pharmaceutical-based treatment that could allow you to not only live a longer life but do so in a way that would allow you to never have to worry about getting any age-related chronic diseases.

And it’s public.

This Could Be a Quick Double

According to the Longevity Fund — a venture capital firm that invests specifically in anti-aging-related companies, including this one — a single age-related indication could be worth a couple hundred billion dollars.

That’s billion with a “B.”

Now, this particular company is set to announce some very important clinical trial results later this month.

If results are positive, this thing could virtually double overnight.

Interestingly, the stock has been steadily climbing over the past few weeks. I don’t know if insiders know something we don’t, but there’s no denying that something is happening here…

aging11

I personally have some skin in this game — I’d be a fool not to.

After all, this could be the first FDA-approved therapy to end age-related diseases — forever. 

If you think Viagra made Pfizer investors rich, imagine what a cure for aging and age-related diseases will do for investors?

This ain’t rocket science, folks. 

Clinical trial results are scheduled to be released in just a few weeks. If those results hit, we’re going to make a mountain of cash.

And of course, I want you to get some of this action too. Which is why I put together this short investor alert for Energy and Capital readers.

I would encourage you to read it now, before those trial results are released. Because once that happens, the chance to double your money on this one will be gone forever.

To a new way of life and a new generation of wealth...

Jeff Siegel Signature

Jeff Siegel

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.

Hydrogen Fuel Cells: The Downfall of Tesla?